← back to search

Nicholas J. Hawkins

UNSW Sydney · AU
Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Genetic factors in colorectal cancer, Cancer Genomics and Diagnostics, Epigenetics and DNA Methylation, and Colorectal Cancer Treatments and Studies.
h-index
47
citations
9,265
works
264
NIH funding
primary concept
Medicine
email

Recent publications

Deep learning‐based H&E‐derived risk scores in colorectal cancer: associations with tumour morphology, biology, and predicted drug response
The Journal of Pathology 2026cited by 1position: middledoi
Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit From Digital Pathology in GI Cancers
Journal of Clinical Oncology 2025cited by 17position: middledoi
Automated deep learning-based assessment of tumour-infiltrating lymphocyte density determines prognosis in colorectal cancer
Journal of Translational Medicine 2025cited by 10position: middledoi
Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer 2025cited by 5position: middledoi
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025cited by 0position: contributordoi
Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study
Cancer Cell 2023cited by 236position: middledoi
Oncomicrobial Community Profiling Identifies Clinicomolecular and Prognostic Subtypes of Colorectal Cancer
Gastroenterology 2023cited by 90position: middledoi
End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study
The Lancet Digital Health 2023cited by 84position: middledoi
Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: middledoi
Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: contributordoi
Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: contributordoi
Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: contributordoi
Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: contributordoi
Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: contributordoi
Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: contributordoi
Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: contributordoi
Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2023cited by 0position: contributordoi
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Clinical Cancer Research 2022cited by 21position: middledoi
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
2022cited by 18position: contributordoi
SNP rs16906252C&amp;gt;T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i> -Methylated Colorectal Cancer
Clinical Cancer Research 2016cited by 41position: middledoi
Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution
Cancer Discovery 2014cited by 468position: middledoi
<i>SMAD2</i>,<i>SMAD3</i>and<i>SMAD4</i>Mutations in Colorectal Cancer
Cancer Research 2012cited by 326position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Robyn L. Ward · The University of Sydney8 papers (2012–2025)Dmitri Mouradov · The University of Melbourne5 papers (2012–2025)Oliver M. Sieber · Parks Victoria4 papers (2012–2023)Peter Gibbs · Dubbo Hospital4 papers (2012–2023)Jitendra Jonnagaddala · UNSW Sydney3 papers (2023–2026)Anuratha Sakthianandeswaren · Parks Victoria3 papers (2012–2023)Ian T. Jones · Western Hospital3 papers (2012–2023)Stephen McLaughlin · Georgia Institute of Technology2 papers (2012–2012)Tanwei Yuan · German Cancer Research Center2 papers (2023–2026)Heike I. Grabsch · Maastricht University2 papers (2023–2026)Fiona Day · Calvary Mater Newcastle Hospital2 papers (2012–2012)Lara Lipton · Westmead Hospital2 papers (2012–2012)Robert N. Jorissen · Flinders University2 papers (2012–2012) · 2 papers (2023–2026)Xiaofeng Jiang · Universiti Sains Malaysia2 papers (2023–2025)Qi Zhao · Dalian Medical University2 papers (2012–2012)Antony W. Burgess · The Royal Melbourne Hospital2 papers (2012–2012)Andrew Ruszkiewicz · South Australia Pathology2 papers (2012–2012)Daniel D. Buchanan · Morehouse College2 papers (2016–2023)Michael Christie · Hudson Institute of Medical Research2 papers (2012–2012)